Hongri Pharmaceutical (300026.SZ) announced first-half results, with net profit of 78.0889 million yuan to mother, a year-on-year decrease of 0.69%

According to the Zhitong Finance App, Hongri Pharmaceutical (300026.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 2.148 billion yuan, a year-on-year decrease of 21.72%. Net profit attributable to shareholders of listed companies was 78.0889 million yuan, a year-on-year decrease of 0.69%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 807.153 million yuan, an increase of 16.67% over the previous year.